The more pronounced disease phenotype in Tlr2/13–/– mice compared with Tlr2/4–/– mice prompted us to introduce the endosome inhibitor CQ as a TLR13 blocker, combined with the mouse-human cross-reactive neutralizing TLR2 monoclonal antibody T2.5 in our murine meningitis model. This evidence concerns the gene TLR2 and meningitis.